LINDSEY WILFERD: Open Payments
NPI 1073255972 · MURRAY, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$735 in 36 payments from 10 companies in 2025. Trend: 2023 $247 · 2024 $506 · 2025 $735
Food & beverage: $735
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 7 | $196 |
| Supernus Pharmaceuticals, Inc. | 11 | $178 |
| Otsuka America Pharmaceutical, Inc. | 5 | $107 |
| Alkermes, Inc. | 3 | $61 |
| E.R. Squibb & Sons, L.L.C. | 3 | $59 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $50 |
| Neurocrine BioSciences, Inc. | 1 | $27 |
| Lundbeck LLC | 1 | $21 |
| ABBVIE INC. | 1 | $19 |
| Janssen Pharmaceuticals, Inc | 1 | $18 |
Products named: Qelbree, FANAPT, REXULTI, HETLIOZ, COBENFY, CAPLYTA, ARISTADA, INGREZZA.
Industry payments across KY — which companies pay providers there.
